Top ▲
Target not currently curated in GtoImmuPdb
Target id: 2892
Nomenclature: jumonji domain containing 6, arginine demethylase and lysine hydroxylase
Family: 1.14.11.- Histone demethylases
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 403 | 17q25.1 | JMJD6 | jumonji domain containing 6, arginine demethylase and lysine hydroxylase | |
Mouse | - | 403 | 11 81.49 cM | Jmjd6 | jumonji domain containing 6 | |
Rat | - | 403 | 10q32.2 | Jmjd6 | jumonji domain containing 6, arginine demethylase and lysine hydroxylase | |
Gene and Protein Information Comments | ||||||
For the human JMJD6 we show details of protein isoform 2. Isoform 1 is slightly longer with 414 amino acids (with ref seq NP_001074930). |
Previous and Unofficial Names ![]() |
bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 | jumonji domain containing 6 | phosphatidylserine receptor | PSR | PtdSerR |
Database Links ![]() |
|
Alphafold | Q6NYC1 (Hs), Q9ERI5 (Mm), Q6AYK2 (Rn) |
ChEMBL Target | CHEMBL4523345 (Hs) |
Ensembl Gene | ENSG00000070495 (Hs), ENSMUSG00000056962 (Mm), ENSRNOG00000000250 (Rn) |
Entrez Gene | 23210 (Hs), 107817 (Mm), 360665 (Rn) |
Human Protein Atlas | ENSG00000070495 (Hs) |
KEGG Gene | hsa:23210 (Hs), mmu:107817 (Mm), rno:360665 (Rn) |
OMIM | 604914 (Hs) |
Pharos | Q6NYC1 (Hs) |
RefSeq Nucleotide | NM_001081461 (Hs), NM_015167 (Hs), NM_033398 (Mm), NM_001012143 (Rn) |
RefSeq Protein | NP_001074930 (Hs), NP_055982 (Hs), NP_203971 (Mm), NP_001012143 (Rn) |
UniProtKB | Q6NYC1 (Hs), Q9ERI5 (Mm), Q6AYK2 (Rn) |
Wikipedia | JMJD6 (Hs) |
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
General Comments |
JMJD6 is a dual arginine demethylase and lysyl hydroxylase of histone and nonhistone proteins [2-3]. It is iron- and 2-oxoglutarate-dependent and is the only known histone arginine demethylase in humans. JMJD6 catalyses the demethylation of H3R2me2, H4R3me2 and H4R3me1 [2]. As a histone arginine demethylase JMJD6 upregulates target gene transcription, and is one of the proteins encoded in the chromosome 17q21-ter gain genetic variant found in human neuroblastoma tissues (and which is a negative prognostic indicator) [1]. As a neuroblastoma tumorigenesis factor JMJD6 is a novel therapeutic target for this cancer [4]. |
1. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H et al.. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med, 340 (25): 1954-61. [PMID:10379019]
2. Chang B, Chen Y, Zhao Y, Bruick RK. (2007) JMJD6 is a histone arginine demethylase. Science, 318 (5849): 444-7. [PMID:17947579]
3. Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, Kessler B, Nielsen ML, Schmitz C, Butler DS, Yates 3rd JR et al.. (2009) Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science, 325 (5936): 90-3. [PMID:19574390]
4. Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC, Bartenhagen C, Bell JL, Mayoh C, Ho N, Tee AE et al.. (2019) JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nat Commun, 10 (1): 3319. DOI: 10.1038/s41467-019-11132-w [PMID:31346162]
1.14.11.- Histone demethylases: jumonji domain containing 6, arginine demethylase and lysine hydroxylase. Last modified on 26/07/2019. Accessed on 11/02/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2892.